哮喘-慢性阻塞性肺疾病重叠的研究进展  

Research progress in asthma-chronic obstructive pulmonary disease overlap

作　　者：薛宇 王晶晶 朱蓉[1] 王立新[1] Xue Yu;Wang Jingjing;Zhu Rong;Wang Lixin(Department of Respiratory and Critical Care Medicine,the Affiliated Huaian No.1 People′s Hospital of Nanjing Medical University,Huaian 223300,China;Department of Respiratory and Critical Care Medicine,Shanghai Pulmonary Hospital,Tongji University School of Medicine,Shanghai 200433,China)

机构地区：[1]南京医科大学附属淮安第一医院呼吸与危重症医学科,淮安223300 [2]同济大学医学院附属上海市肺科医院呼吸与危重症医学科,上海200433

出　　处：《国际呼吸杂志》2024年第4期467-471,共5页International Journal of Respiration

基　　金：国家自然科学基金(82100063)。

摘　　要：支气管哮喘(哮喘)和慢性阻塞性肺疾病是2种常见的慢性阻塞性气道疾病,尽管两者均为异质性疾病,但较多患者同时具有两者的特征,临床上现多将其描述为哮喘-慢性阻塞性肺疾病重叠(ACO)。虽然ACO目前仍缺乏公认的定义,但明确的是ACO患者急性加重更加频繁,生活质量更差,疾病负担也更加严重。故本文对ACO目前的流行病学、发病机制、生物标志物、临床特点和治疗作一综述。Bronchial asthma(asthma)and chronic obstructive pulmonary disease are two common chronic obstructive airway diseases.Although both are heterogeneous,many patients have features of both,which is now mostly described clinically as asthma-chronic obstructive pulmonary disease overlap(ACO).Although there still lacks recognized definition of ACO,it is clear that patients with ACO experience more frequent acute exacerbations,poorer life quality,and a greater disease burden.Therefore,this article reviews the epidemiology,pathogenesis,biomarkers,clinical features,and treatment of ACO.

关 键 词：哮喘-慢性阻塞性肺疾病重叠 流行病学 发病机制 诊断 治疗 

分 类 号：R562.25[医药卫生—呼吸系统] R563.9[医药卫生—内科学]